Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amelubant (BIIL 284) in Rheumatoid Arthritis
NCT02247375Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2000
- Primary completion
- May 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amelubant in rheumatoid arthritis (RA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Changes from baseline in CD11b/CD18 (Mac-1) expression, Plasma concentrations of BIIL 284 BS and metabolites and 3 more. Started Jan 2000; status: completed.
02
Drugs
amelubant
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02247375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02247375.